BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36992422)

  • 1. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
    Segura EER; Ayoub PG; Hart KL; Kohn DB
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Era for Hemoglobinopathies: More Than One Curative Option.
    Psatha N; Papayanni PG; Yannaki E
    Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy for Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease.
    Leonard A; Tisdale JF; Bonner M
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):769-795. PubMed ID: 35773052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy Approaches to Hemoglobinopathies.
    Ferrari G; Cavazzana M; Mavilio F
    Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
    Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
    Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
    Payen E; Leboulch P
    Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
    Dong AC; Rivella S
    Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
    Magrin E; Miccio A; Cavazzana M
    Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Therapy for β-Hemoglobinopathies.
    Cavazzana M; Antoniani C; Miccio A
    Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by
    Koniali L; Flouri C; Kostopoulou MI; Papaioannou NY; Papasavva PL; Naiisseh B; Stephanou C; Demetriadou A; Sitarou M; Christou S; Antoniou MN; Kleanthous M; Patsali P; Lederer CW
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene Therapy for beta-thalassemia.
    Malik P; Arumugam PI
    Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.
    Rosanwo TO; Bauer DE
    Mol Ther; 2021 Nov; 29(11):3163-3178. PubMed ID: 34628053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapy for Hemoglobinopathies.
    Cavazzana M; Mavilio F
    Hum Gene Ther; 2018 Oct; 29(10):1106-1113. PubMed ID: 30200783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.
    Leonard A; Bertaina A; Bonfim C; Cohen S; Prockop S; Purtill D; Russell A; Boelens JJ; Wynn R; Ruggeri A; Abraham A
    Cytotherapy; 2022 Mar; 24(3):249-261. PubMed ID: 34879990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for hemoglobinopathies: the state of the field and the future.
    Chandrakasan S; Malik P
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):199-216. PubMed ID: 24589262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
    Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
    Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.